Analyst Ratings for Enliven Therapeutics (ELVN)
ELVN Rating Summary
ELVN Price Target Summary
- Highest: $82.00 (Stifel)
- Lowest: $55.00 (Clear Street)
- Average: $72.82
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
=
Avg. $ Target:
$72.82 (+95.1%)
* Over Last 12-Mos
Rating Score: 10 / 10
Percentile Rank: 95%
Rating Score: 10 / 10
Percentile Rank: 95%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/2/2026 | Morgan Stanley | Sean Laaman | New Coverage | Overweight (N/A) |
70.00 (N/A) |
45.84 (37.32) |
-18.59% | Details |
| 10/1/2026 | JPMorgan | Priyanka Grover | New Coverage | Overweight (N/A) |
75.00 (N/A) |
46.51 (37.32) |
-19.76% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
